LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Kodu・Aktsiate loetelu・BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

Suletud

Sektor Tervishoid

84.04 -1.09

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

83.68

Max

84.71

Põhinäitajad
By Trading Economics
Sissetulek	19M 107M
Müük	63M 712M
P/E Sektori keskmine	77.67 103.001
Aktsiakasum	0.96
Kasumimarginaal	15.052
Töötajad	3,401
EBITDA	26M 162M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+31.27 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. okt 2024

Turustatistika
By TradingEconomics
Turukapital	-526M 17B
Eelmine avamishind	85.13
Eelmine sulgemishind	84.04

Uudiste sentiment

By Acuity

36%

64%

76 / 365 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

N/A / 90.02 Toetus ja vastupanu

BioMarin Pharmaceutical Inc Graafik

Seotud uudised

10. juuni 2024, 17:41 UTC

Suurimad hinnamuutused turgudel

Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion

21. aug 2024, 11:30 UTC

Peamised uudised

S&P 500 Futures Up In Premarket Trading; Target, Keysight Technologies Lead

Võrdlus sarnastega

Hinnamuutus

BioMarin Pharmaceutical Inc Prognoos

Hinnasiht

By TipRanks

31.27% tõus

12 kuu keskmine prognoos

Keskmine 110.37 USD 31.27%

Kõrge 130 USD

Madal 72 USD

Põhineb 22 Wall Streeti analüütiku instrumendi BioMarin Pharmaceutical Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

22 ratings

Osta

Hoia

Müü

Põhineb 22 analüütiku instrumendi BioMarin Pharmaceutical Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

N/A / 90.02Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

76 / 365 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.